Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TGTX
TGTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TGTX News
TG Therapeutics Completes Enrollment in Phase 3 Trial for BRIUMVI
4d ago
NASDAQ.COM
TG Therapeutics Completes Enrollment in Phase 3 BRIUMVI Trial
5d ago
Newsfilter
Analysis of XBI ETF Trading Dynamics
Apr 07 2026
NASDAQ.COM
Analysis of XBI ETF's 52-Week Price Fluctuations
Mar 30 2026
NASDAQ.COM
TG Therapeutics Secures $750 Million Credit Facility
Mar 19 2026
NASDAQ.COM
TG Therapeutics Secures $750M Credit Facility
Mar 19 2026
seekingalpha
ACT Capital Management Acquires Stake in TG Therapeutics
Mar 16 2026
Fool
Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD
Mar 12 2026
Newsfilter
BRIUMVI Shows Significant Efficacy in Highly Active Relapsing Multiple Sclerosis
Mar 09 2026
Newsfilter
TG Therapeutics Announces BRIUMVI® Presentation Schedule at AAN 2026
Mar 06 2026
Newsfilter
TG Therapeutics Reports Strong Q4 2025 Earnings and Growth Outlook
Feb 26 2026
seekingalpha
TG Therapeutics Q4 Earnings Miss Expectations with Revenue Growth
Feb 26 2026
seekingalpha
TG Therapeutics Set to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
TG Therapeutics to Host Q4 2025 Earnings Call
Feb 23 2026
Newsfilter
BRIUMVI Shows Significant Efficacy Over Five Years in MS Treatment
Feb 17 2026
Newsfilter
Soleus Capital Increases Stake in Celcuity
Feb 13 2026
Fool
Show More News
